Many essential biological processes are regulated through proximity, from membrane
receptor signaling to transcriptional activity. The ubiquitin-proteasome system controls …

Targeted protein degradation (TPD) technology has gradually become widespread in the
past 20 years, which greatly boosts the development of disease treatment. Contrary to small …

Many cereblon (CRBN) ligands have been used to develop proteolysis targeting chimeras
(PROTACs), but all are reversible binders of the E3 ubiquitin ligase. We recently described …

Abnormally expressed or malfunctioning proteins may affect or even damage cells, leading
to the onset of diseases. Proteolysis targeting chimera (PROTAC) technology has been …

Targeted protein degradation by small-molecule degraders represents an emerging mode of
action in drug discovery. Proteolysis targeting chimeras (PROTACs) are small molecules …

Mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) are the crucial part of the RAS-
RAF-MEK-ERK pathway (or ERK pathway), which is involved in the regulation of various …

Targeted protein degradation (TPD) by PROTACs is a promising strategy to control disease-
causing protein levels within the cell. While TPD is emerging as an innovative drug …

Protein N-terminal methylation catalyzed by N-terminal methyltransferase 1 (NTMT1) is an
emerging methylation present in eukaryotes, playing important regulatory roles in various …

Covalent ligands are a versatile class of chemical probes and drugs that can target
noncanonical sites on proteins and display differentiated pharmacodynamic properties …

Challenging disease targets necessitate new approaches for therapeutic intervention.
Rewiring protein-biomolecule interactions with proximity-inducing agents extends …